Although most marketed MAO drugs are long-lasting irreversible inhibitors, reversible inhibitors have been developed to avoid prolonged irreversible effects: for example, moclobemide and safinamide, which are selective for MAO-A and MAO-B, respectively, and are prescribed as an antidepressant and for the treatment of PD, respectively [109,111,112]. Here, MAOA is linked to Parkinson disease.